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Endoscopicendoluminalradiofrequencyablation(RFA)isanovelandpromisingmodalityforBarrett’sesophagus(BE)treatment.
Actually the only surveillance method after the ablation treatment is random biopsies throughout the whole treated area. Confocal
laser endomicroscopy (CLE) is a new endoscopic imaging tool that permits high-resolution microscopic examination of the
gastrointestinal tract. The technology has garnered increasing attention because of its ability to provide real-time “optical” biopsy
specimens, with a very high sensitivity and speciﬁcity. This paper summarize the potential application of CLE in the surveillance
of the reepithelialization of BE, after endoscopic RFA.
1.Introduction
CLE is a new endoscopic technique, which allows surface in
vivo microscopic analysis during ongoing endoscopy, using
systemically or topically administered ﬂuorescent agents.
CLE uses a single-line laser with a wavelength of 488nm to
generate optical histologic slices of 7µm[ 1]. It allows target-
ed biopsies to be taken, potentially improving the diagnostic
rate in certain gastrointestinal diseases. The technology has
garnered increasing attention because of its ability to provide
real-time “optical” biopsy specimens, with a very high sensi-
tivity and speciﬁcity [2]. Worldwide experience with CLE for
upper gastrointestinal malignant and premalignant lesions
is still limited. Potential clinical applications are presented,
including diagnosis of NERD, BE [3, 4], early squamous cell
carcinoma in the esophagus [5], atrophic gastritis, gastric
intestinal metaplasia, dysplasia and gastric cancer [6], celiac
disease [7], ulcerative colitis [8], and colorectal cancer [9].
The incidence of esophageal adenocarcinoma has risen
steadily over the past 10 years. Patients with BE are at in-
creased risk for the development of adenocarcinoma. The
ﬁeld of BE ablation has advanced dramatically in recent
years. Endoscopic ablation is now viewed as a legitimate
ﬁrst-linetreatmentoptionforhealthypatientswithintestinal
metaplasia (IM), low-/high-grade dysplasia and, in some
cases,earlyadenocarcinoma,onthebasisofongoingresearch
[10]. Recently there has been a growing literature related to
the endoscopic ablation of BE using RFA [11, 12].
ThiscasehighlightsanotherpotentialapplicationofCLE:
the BE surface study after endoscopic endoluminal RFA.
2.CaseReport
A 70-year-old man with a history of long-standing reﬂux,
symptomatic GERD, histologic evidence of BE without dys-
plasia and a large hiatal hernia, was referred to our depart-
ment for further management. After a Collis-Nissen surgical
treatment, the endoscopic followup, over a 3-year period,
revealed unchanged histological features: IM within the 8cm
segment of endoscopic BE (C7M8—Prague C & M Criteria),
without dysplasia. These endoscopies were performed both
with and without methylene blue stain, by using 4-quadrant
biopsies every 2cm throughout the BE (Seattle’s biopsy
protocol). After this surveillance period according with the
patient and after an informed consent was obtained, we
start to treat the BE by endoscopic endoluminal RFA (Barrx2 Case Reports in Gastrointestinal Medicine
Figure 1: RFA catheter deﬂated inside the esophagus after the ﬁrst
ablating session. On the right is clearly visible the greyish ablated
mucosa.
Halo 360 System). Under monitored anesthesia care and
after the endoscopic esophageal landmarks were deﬁned, the
esophageal wall was sprayed with acetylcysteine 1% for the
ablation procedure. The esophageal diameter was sized with
a sizing catheter, passed endoscopically over a stiﬀ guidewire,
and then removed. An autosizing balloon of the ablation
system was used to determine the diameter of the esophagus
and allow good contact between the radiofrequency delivery
system (balloon/electrodes) and the esophageal wall on one
hand and not apply excessive pressure on the other. The
RFA procedure started moving from distally to proximally,
and the balloon was progressively repositioned allowing a
very small overlap with the previous treated zone (Figure 1).
The exudative material caused by the burn was scraped oﬀ
the esophagus with aggressive washing and an endoscopic
cap (used for mucosal resection). Because of the length,
the ablation was repeated until the 2/3 of the BE (6cm),
were treated with radiofrequency energy, and carried out the
treatment of the last 2cm after two months (as suggested
by the producers of the ablation system). The patient was
discharged the same day with a prescription of esomeprazole
40mg twice a day for the ﬁrst month and 40mg every day
until the following examination. He was also instructed to
eat only a soft diet for 2–4 days, use liquid acetaminophen
for the eventual discomfort, and avoid aspirin and anti-
inﬂammatory drugs for 7 days.
After a month, we decided to control the treated area of
theesophagus.Undermonitoredanesthesiacare,themucosa
was initially examined with standard white-light endoscopy.
Subsequentlythepatientwasintubatedwithaconfocalendo-
microscope (EC-3870CIFK; Pentax, Tokyo, Japan). After an
intravenous injection of 5mL ﬂuorescein sodium 10%, the
6cm treated area was circumferentially imaged and stored
digitally. We collect 78 images at a scan rate of 0,8 frames
per second (1024 × 1024 pixels), using an optical slice
thickness of 7µm, with lateral and axial resolution of 0.7µm.
The microscopic ﬁeld of view was 475 × 475µmw i t ha n
inﬁltration depth of the blue laser light from the surface
to 250µm. Endomicroscopy was performed in the whole
treated esophagus, in the 4 quadrants mimicking the Seattle
(a)
(b)
Figure 2: CLE image and histologic aspect (trasversal section) of
the proximal treated esophageal area. Normal squamous esophagus
showing individual epithelial cells and intrapapillary capillary
loops.
biopsy protocol [13], from the surface to the deeper portion.
The site of interest was placed at the lower left corner of the
CLE window and the distal tip of the endoscope in contact
withthemucosausingbluelaserasguide.Thepositionofthe
focal plane within the specimen was adjusted using the but-
tons on the endoscope control panel. During the procedure,
agentlesuctionwasusedtostabilizetheendomicroscopeand
minimize excessive movement, reducing motion artifacts.
All images revealed a typical regular-appearing subepithelial
capillary network. The capillary loops within the papillae
were visible due to the high contrast of the ﬂuorescein within
thevascularstructures,surrounded bynormal epithelial cells
(Figures 2 and 3) .T h es a m ep r o c e d u r ew a sa l s op e r f o r m e d
over the proximal not treated surface. In that case, the CLE
revealed regular-shape subepithelial capillaries underneath
a columnar-lined epithelium with presence of focal dark
mucin goblet cells in the upper parts of the mucosal layer
(Figure 4). At that point, we concluded the examination
performing 4-quadrant biopsies every 1 to 2cm throughoutCase Reports in Gastrointestinal Medicine 3
Figure3:CLEimageofthetreatedesophagealarea,middleportion.
Normal squamous esophagus showing individual epithelial cells
and intrapapillary capillary loops.
both treated and not treated surface. The “optical biopsy”
site was located 5mm immediately to the left of the suc-
tion-marked area, obtained during the CLE examination.
Histopathologic examination of the biopsy specimens con-
ﬁrmed the normal squamous epithelium over the whole
treated esophageal area without any evidence of residual IM
beneath the newly generated epithelium conﬁrming the CLE
diagnosis. The residual columnar epithelium was completely
ablated with a single session of Halo 90◦.
3. Discussion
Considering the fact that the RFA is a relatively new tech-
nique and there are no long-term studies showing an irre-
versibledisappearanceoftheIMwithcompletehealingofthe
esophagus, after many years, the only surveillance method is
the random biopsies throughout the whole treated area. The
longest follow-up study for patients, underwent endoscopic
ablation of nondysplastic BE, is a prospective multicenter US
trial published 1 year ago including 50 patients [12]. Of 1473
esophageal specimens obtained at 5 years, 85% contained
lamina propria or deeper tissue with complete response
demonstratedin92%ofpatients,while8%hadfocalIM,and
there were no buried glands, dysplasia, strictures, or serious
adverse events.
Eﬀective BE ablation presumes complete eradication of
the abnormal epithelium, inclusive of its stem cells that are
believed to accumulate oncogenetic abnormalities that lead
to the phenotypic expression of dysplasia and cancer in
the epithelial cells [14–17]. Ineﬀective (incomplete) ablation
leaves IM behind and increases the risk for IM to become
buriedbeneaththeneosquamousepithelium[18].Thislatter
phenomenon is also known as subsquamous intestinal meta-
plasia (SSIM). After the eradication of the BE epithelium,
wound healing ensues followed by restoration, in most cases,
of a thin nascent squamous epithelium. This neosquamous
epithelium thickens over time to a normal stratiﬁed squa-
mous epithelium. Several theories exist as to the source of
(a)
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Figure 4: CLE image and histologic aspect (trasversal section) of
the untreated esophageal zone: columnar lined epithelium with
presence of focal mucin goblet cells (arrows), pathognomonic of
gastric type mucosae with focal intestinal metaplasia.
the neosquamous epithelium, including encroachment of
adjacent squamous epithelium, extension of cells from the
submucosal gland duct lining with conversion to squamous
epithelium, and circulating pluripotent stem cells which
deposit in the wound and transform to squamous stem cells
[19, 20]. Biddlestone et al. have reported that SSIM, when it
occurs, resides in the deep portion of the epithelium or in
the lamina propria [21]. Adler et al. revealed densely packed
Barrett’sesophagusglandsbeneath300–500µmofsuperﬁcial
tissue and distorted layered architecture with good histologic
correlation at biopsy specimens, using three-dimensional
optical coherence tomography [22].
The ﬁeld of CLE has advanced rapidly with multiple
studiespublishedandpresentedinthepast4years.Published
randomized controlled studies suggest that chromoendos-
copy-aided endomicroscopy allows targeting of mucosal
biopsy, thereby, increasing the diagnostic yield and decreas-
ing biopsy number. By using the current CLE system, the
mucosa can be analyzed at a magniﬁcation of about 1000x,4 Case Reports in Gastrointestinal Medicine
but with a maximum penetration depth of the scanning
laser light of only 250µm (too far from the hypothetical
residualburiedIM),evaluatingchangesinvessels,connective
tissue, and cellular architecture during ongoing endoscopy
but without the possibility to diagnose SSIM.
CLE can be performed relatively easily over the esopha-
gus to identify architectural and vascular changes; endomi-
croscopic changes suggesting the presence of dysplastic or
neoplastic changes within BE mucosa include the presence
of irregular, black cells with a loss of the normal cellular
pattern and distorted subepithelial capillaries with leakage
of ﬂuorescein. Since its depth limitation; therefore, we can
aﬃrm that CLE is a potentially future diagnostic tool in
the surveillance of BE after RFA. Nowadays CLE in Barrett’s
esophagus after RFA can play an important role in the
diagnosis of residual superﬁcial glandular mucosa and/or
revealing dysplastic changes of the tissue.
In conclusion residual SSIM afterRFA ablation is still not
visible, but further reﬁnement in confocal imaging, based
on the increase of the penetration depth of the scanning
laser light up to 500–600µm over the lamina propriae and
the eventually 3D reconstruction, could increase in the next
future the role of CLE in the surveillance of BE.
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